CA
NZ
UK
AU
IND
US
For a disease that has spent decades at the margins of pharmaceuticalInvestment, hereditary angioedema has never lacked for urgency. Its sufferers endure episodes of sudden, severe swelling — in the face, limbs, gut and, most dangerously, the throat — triggered by stress, infection or, …
Eli Lilly (NYSE:LLY) is one of the most strategically transformed large-cap pharmaceutical companies of the modern era. Over the past several years, it has gone from a diversified pharma with steady but unspectacular growth into the dominant Western operator in the GLP-1 metabolic franchise …
Edwards Lifesciences (NYSE:EW) opened fiscal 2026 with a quarter that reinforced the investment case for its concentrated structural heart strategy. Total revenue of $1.65 billion grew 12.7% year-over-year, clearing analyst expectations. Adjusted EPS of $0.78 beat the $0.73 forecast, while GAAP EPS came in …
A Beat That Failed to Reassure Markets
HeartBeam has announced a $10 million public offering at a strategically important stage in its corporate development. Unlike many small-cap financings that are purely defensive in nature, this transaction carries an additional signaling effect due to participation from the company’s first commercial customer and …
Kazia Therapeutics has re-entered investor discussions following a favorable analyst initiation that assigned a Buy rating and a $25 price target. The optimism is centered on paxalisib, the company’s lead oncology candidate, and expectations for multiple upcoming catalysts over the next two years.
Aligos Therapeutics has delivered a meaningful operational and regulatory update for its chronic hepatitis B virus program. The company announced that the independent Data Safety Monitoring Board recommended continuation of the Phase 2 B-SUPREME study, while also endorsing expansion of a key patient cohort.
Immutep has moved back into focus after announcing a meaningful regulatory milestone for its lead immunotherapy candidate. The company received U.S. Food and Drug Administration Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, adding momentum to its oncology development strategy.
Clearmind Medicine has completed a financing transaction that quickly transitioned from debt issuance into equity conversion. The company issued $1.75 million in convertible promissory notes and received $1.58 million in cash proceeds, before the full principal amount was converted into shares by CLA Investors.
Precision BioSciences has taken another operational step forward in the development of PBGENE-HBV, its investigational gene-editing therapy for chronic hepatitis B. The company announced Clinical Trial Application approval to expand the global ELIMINATE-B study into France and Romania.
Please wait processing your request...